&#xa0;
defaultWritten evidence from defaultDr Ben defaultGoldacredefault, Sir Iain Chalmers, Dr Trish Grovesdefault, Dr Fiona defaultGodleedefault, Dr Virginia Barbour (GMC0019)default&#xa0;
default&#xa0;
defaultBen 
defaultGoldacre
default is a medic 
defaultand 
defaultacademic who writes 
defaultfor the 
defaultpublic on misuses of scientific evidence
default, including a recent book 
defaultabout 
defaultproblems in medicine [1]
default. 
defaultIain Chalmers is co-founder of the Cochrane Collaboration, and director of the James Lind Library. Trish Groves is 
defaulta medic and 
defaultDeputy Editor of the British Me
defaultdical Journal. 
defaultFiona 
defaultGodlee
default is 
defaulta medic and 
defaultEditor in Chief of the British Medical Journal. Virgin
defaulti
defaulta Barbour is 
defaulta medic and 
defaultEditor in Chief of 
defaultPLoS
default 
defaultMedicine
default. 
defaultAll are 
defaultalso
default co-founder
defaults
default of 
defaultAllTrials
default, a campaign 
defaultwith widespread public and professional support 
defaultc
defaultalling for all trial results on currently used treatments to be made publicly available
default [
default2
default]
default. 
default&#xa0;
defaultWe are 
defaultwriting to raise three areas where the assistance of the GMC would be very valuable to patients and the public
default, and where such intervention is timely
default.
default&#xa0;
default1.default Pdefaultromoting pdefaultarticipatdefaultion defaultin research.default 
defaultThe GMC guidance previously stated that doctors “
defaultmust work with colleagues and patients . . . to help resolve uncertainties about the effects of treatments” (
defaultpara
default 14f)
default. 
defaultHowever, in 
default2013 
defaultthe GMC 
defaultremoved 
defaultthis clause
default [3]
default. 
defaultT
defaulthis decision should be reversed, and the clause reinstated
default. Research is the only way we can identify and reduce uncertainty about which treatments work best. At present there is considerable red tape obstructing doctors who seek to conduct research
default. M
defaultuc
defaulth of 
defaultthis red tape 
defaultis unnecessary; the incentives to participate in research do not reflect the urgency of the 
defaultneed for better evidence to guide clinical practice
default. 
defaultT
defaulthere are many documented cases where patients have suffered and died unnecessarily
default,
default because
default doctors 
defaulthave 
defaultfailed to 
defaultrecognise
default uncertainty
default and conduct research to address it
default [3]
default. The GMC requires doctors to practice medicine based on research evidence. 
defaultWe cannot 
defaultdo so 
defaultwithout 
defaultproducing 
defaultthis 
defaultevidence, and doctors have a responsibility to 
defaultall 
defaultpatien
defaultts to help identify and reduce uncertainty in everyday clinical practice.
default This should be 
defaultunambiguously 
defaultreflected in GMC guidance
default, as it was until 2013
default.
default&#xa0;
default2. A register for doctors’ conflicts of interestdefaultThere is a need for a register of doctors' 
defaultc
defaultonflicts o
defaultf 
defaulti
defaultnterest, similar that for MP's. At present, doctors may receive 
defaultconsultancy 
defaultincome, 
defaultresearch 
defaultfunding, sponsorship, travel, hospitality and free educational activity sponsored by the pharmaceutical and device industries
default; m
defaultany doctors serving on Clinical 
defaultCommissioning Groups now run companies whose services are commissioned by their own CCG
default; m
defaultany media doctors receive income from PR or medical companies
default; and so on
default. 
default&#xa0;
defaultC
defaultonflicts of interest cannot be prevented, nor would it be desirable to do so: there is mu
defaultch good work done by doctors collaborating with industry. 
defaultThese payments 
defaultalso 
defaultdo not mean that doctors are corrupt. However, t
defaulthere is extensive research evidence showing that 
defaultdoctors with financial 
defaultconflicts of interest 
defaultoften 
defaultexpress 
defaultmore 
defaultfavourable
default 
defaultviews on 
defaultthe 
defaulttreatments
default in question
default,
default when compared to 
defaultdoctors who have not received such payments
default. 
defaultI
defaultt is 
defaulttherefore 
defaultimportant that information about these conflicts of interest is transparent
default. It
default is currently extremely hard - and in many cases impossible - 
defaultfor patients, colleagues, 
defaultpatients 
defaultand the public to establish who 
defaulthas paid
default a doctor.
default&#xa0;
default&#xa0;
defaultIndustry and self-
defaultregulatory approaches to this have failed, and will most likely to continue to do so. The Ethical Standards in Health and Life Sciences Group (co-chai
defaultred by the ABPI and the Royal College of Physicians) is a particularly concerning example: they produced "guidelines" documents for doctors which contained a number of false claims, and gave false reassurance on important matters of patient safety, before 
defaultdisbanding
default in October 2013
default, 
defaultwithout ever giving 
defaulta clear account of their activities
default [4] [5] [6]
default. Furthermore, declarations of payments to doctors from the pharmaceutical industry 
default(which has often been proposed, but never delivered) 
defaultwould be
default 
defaultinsufficient, a
defaults 
defaultthis sector 
defaultcover
defaults
default only a small proportion of the many sources of 
defaultpayments to 
defaultdoctors
default, as
default described above
default. 
default&#xa0;
defaultThe GMC requires doctors to re-register each year, 
defaultand 
defaultmaintains a public register
default. It is therefore 
defaultin 
defaulta clear position to 
defaultrequest 
defaulta simple decla
defaultration 
defaultof financial conflicts of interest 
defaultfrom each doctor in the UK
default, 
defaultannually, 
defaultand make 
defaultthis information 
defaultpublicly available
default on the register
default.
default&#xa0;
default&#xa0;
default3. Action on withheld trial resultsdefaultThe problem of clinical trial results being 
defaultwitheld
default, on treatments in curren
defaultt use, continues to undermine the evidence base for medicine. The best currently available evidence suggests that around half of all trials have their results withheld
default [7]
default. Doctors, patients, researchers and payers cannot make informed decisions about whic
defaulth treatments are best
default,
default when half 
defaultof all 
defaulttrial results are 
defaultunavailable
default. This problem has not been adequately addressed by medical 
defaultand
default academic professional bodies, regulators, or industry. 
defaultThere has also been a worrying trend for some in both industry and 
defaultmedicine to give false reassurance, claiming that the problem has been fixed. This poses a significant threat to patient care.
default&#xa0;
defaultThe Science and Technology Select Committee called on the government to take action 
defaultover 
defaultthis issue
default in September 2013
default [8]
default. 
defaultThe H
defaultealth Committee called on the GMC 
defaultto take action on this issue in January 
default2013 
default[
default9
default]. 
defaultThe 
defaultBritish Medical Association
default passed a motion 
defaultin June 2013 
default[10] [11] 
default[12] 
defaultstating that:
default&#xa0;
default&#xa0;
default“(
defaulti
default) Selective non-publication of unflattering trial data is research misconduct
default; 
default“
default(ii) Registered medical practitioners who give grounds to believe they have been involved in such conduct should have their fitness to practice assessed by the GMC
default.” 
default&#xa0;
defaultIt would therefore be useful if the 
defaultGMC could 
defaultprominently 
defaultclarify their position
default, 
defaultand strengthen the wording of their guidance
default, requiring that 
defaultany 
defaultdoctor
default 
defaultworking on 
defaulta 
defaulttrial
default 
defaultboth past and present - on all treatments currently in use – 
defaultis 
defaultresponsible for ensuring that the trial is 
defaultregistered
default,
default with 
defaultits 
defaultresults made publicly available
default withi
defaultn a year of completion
default; and forbidden from entering into contracts with trial sponsors that 
defaultrelinquish access to data 
defaultand prevent dissemination of results
default. 
default&#xa0;
defaultWhile only a small proportion of doctors actively participate in conducting 
defaultrandomised
default trials, a m
defaultuch larger number 
defaultmake a valuable
default positive
default contribution by 
defaultrecruit
defaulting and encouraging 
defaultpatients to participate 
defaultin others’ 
defaulttrials research.
default They too have a responsibility around missing trial results.
default 
defaultPara 49d of Good Medical Practice says that doctors must work in partnership with patients, providing 
default“
defaultany other information patients need if they are asked to agree to be involved in teaching or 
defaultresearch
default”
default. This would be greatly
default&#xa0;
defaultstrengthened by adding a ne
defaultw clause
default&#xa0;
default49e 
default“
defaultDoctors should advise patients to
default&#xa0;
defaultparticipate in a clinical trial only if: (1) the study protocol has been registered and made publicly available; (2) the protocol refers to systematic reviews of existing evidence showing that the trial is ju
defaultstified; and (3) each patient
default&#xa0;
defaultreceives a written assurance that the full study results will be published and sent to all participants who indicate th
defaultat they wish to receive them.
default”
default [
default13
default] [
default14
default]
default&#xa0;
defaultThe GMC 
defaultdo good work on misdeeds 
defaultby individuals 
defaultin individual stu
defaultdies
default. However
default, 
defaultit is 
defaultinadequate and inconsistent to 
defaultonly 
defaulthold individual studies to hig
defaulth
default standards, 
defaultwhen 
defaultthe biases we are seeking to exclude 
defaultcan re-emerge
default 
defaultfurther down the chain
default. 
defaultEven when all trials are conducted perfectly, i
defaultf 
defaultthose 
defaultwhole studies 
defaultwith un
defaultflattering results 
defaultare withheld from the public record
default – as we know they commonly are -
default then we are 
defaultoverall 
defaultmisled on the risks and benefits of treatments
default,
default 
defaultas surely as if the data 
defaultfrom 
defaultthe individual studies themselves were fraudulent
default.
default The GMC are in a po
defaultsition to police the withholding of trial results
default,
default as they 
defaultpolice 
defaultother forms of research misconduct.
default It is in patients’ interests that they should do so.
default&#xa0;
defaultReferences. default&#xa0;
default[1] “Bad 
defaultPharma
default: how medicine is broken, and how we can fix it” Ben 
defaultGoldacre
default, 4
defaultth
default Estate, 2013
default[2] www.alltrials.net
default[3] 
defaultRoberts I, 
defaultChaudhry
default B, Chalmers I. New GMC guidance takes a major, ethically flawed, backward step. BMJ. 2013;346(jun18 2):f3879–f3879. 
defaulthttp://www.bmj.com/conten
defaultt/346/bmj.f3879
default[4] 
defaultArie
default S. Doctors’ groups are criticised for endorsing pro-industry guidelines. BMJ. 2013;347(oct09 2):f6066–f6066. doi:10.1136/bmj.f6066.
default[5] 
defaultArie
default S. How a marriage with big 
defaultpharma
default ended in divorce. BMJ. 2013;347(oct08 5):f6062–f6062.
default doi:10.1136/bmj.f6062.
default[6] 
defaultGoldacre
default B, Carroll D, Hall E. Guidelines for collaboration with industry should be transparent. BMJ. 2013;347(oct09 4):f6100–f6100. doi:10.1136/bmj.f6100.
default[7]
default 
defaultHuser
default V, 
defaultCimino
default JJ. Linking ClinicalTrials.gov and 
defaultPubMed
default to Track R
defaultesults of Interventional Human Clinical Trials. 
defaultPLoS
default ONE. 2013;8(7):e68409. doi:10.1371/journal.pone.0068409.
default[8] 
defaultScience and Technology Committee, Third Report, Clinical Trials, 9 September 2013. 
defaulthttp://www.parliament.uk/business/committees/committees-a-
defaultz/commons-select/science-and-technology-committee/news/130916-clinical-trials-report-published/
default[9] 
defaultHealth Committee, 
defaultEighth 
defaultReport, National Institute for Health and Clinical Excellence, 
default16 
defaultJanuary 2013. 
defaulthttp://www.parliament.uk/business/committees/commit
defaulttees-a-z/commons-select/health-committee/news/13-01-15/
default[
default10
default] 
defaulthttp://bma.org.uk/working-for-change/improving-and-protecting-health/clinical-trials
default 
default[11
default] 
defaulthttp://ecancer.org/journal/news/4200-bma-----non-publication-of-trials-results-is-research-misconduct.php
default 
default[1
default2
default] 
defaulthttp://www.alltrials.net/2013/bma-votes-that-non-publication-of-trials-results-is-research-misconduct/
default[13] Chalmers I,
default&#xa0;
defaultGlasziou
default P,
default&#xa0;
defaultGodlee
default F. All trials must 
defaultbe registered and the results published.
default&#xa0;
defaultBMJ
default&#xa0;
default2013;346:f105
default[14]
default&#xa0;
defaultEvans I, Thornton H, Chalmers I, 
defaultGlasziou
default P. Testing treatments. Pinter and Martin, 2011.
default&#xa0;
defaultwww.testingtreatments.org
default.
default&#xa0;
defaultDecember 2013
default&#xa0;
default&#xa0;
default